In a further sign of national vaccine planning readiness, Canada secured a contract to procure 37 million syringes—roughly the same size as the population—for delivery of shots for the entire population. The nation recently secured a national deal with the frontrunning vaccine maker, CanSino Biologics.
Anita Anand, Public Services and Procurement Minister, facilitated the purchase from the Canadian branch of Becton Dickinson, the global medical device and appliances company. Although there is no definitive timeline for the actual delivery, this seems to be a mass vaccination planning effort still in a relatively early stage, reports The Record.
As TrialSite News has reported, CanSino Biologics earned the entire country’s business. The nation’s National Research Council of Canada, along with the Chinese company, is conducting the sole COVID-19 vaccine study authorized by Health Canada.
Other COVID-19 Studies
According to The Record, the Canadian government authorized a total of 38 clinical trials involving potential SARS-COV-19 treatments. These trials study test drugs ranging from hydroxychloroquine to inhaled nitric oxide for infection patients to cellular immunotherapy.
CanSino Biologics Investor Watch
The company trades as of this writing at $24.51. According to Yahoo Finance, their 52 week high/low equals $7.50 and $59.99.